Brief Report: Heplisav-B Seroprotection in People With HIV: A Single-Center Experience.

Journal of Acquired Immune Deficiency Syndromes : JAIDS
Samuel R SchnittmanDavid Sears

Abstract

Heplisav-B, a hepatitis B virus (HBV) vaccine with an immunostimulatory adjuvant, was FDA approved in 2017 for adults ≥18 years. In randomized controlled trials, Heplisav-B demonstrated seroprotection rates (SPR) of 90%-95% versus 65%-80% for Engerix-B. No studies have included people with HIV (PWH), and the SPR and its predictors in this population are unknown. Quaternary care center HIV clinic. This retrospective cohort study evaluated PWH aged ≥18 years without current HBV seroprotection (anti-HBV surface antibody level [anti-HBs] <10 mIU/mL) who were administered Heplisav-B. Patients without post-immunization titers were excluded. The primary outcome was the SPR, the proportion of participants with HBV seroprotection at any point after the first vaccination. Among 64 PWH included, median time to anti-HBs measurement after vaccination was 13 weeks. The median age was 58 years, 81% were men, and 95% had a viral load <200. The SPR was 81% in the entire cohort (and 86% in those without significant non-HIV immunosuppression), 79% in those with no prior HBV vaccination and no anti-HBc positivity, and 84% in those with prior vaccine nonresponse. Lower current and nadir CD4+ counts were associated with progressively lower seroprote...Continue Reading

References

Mar 30, 1999·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·J F ColinP Marcellin
Dec 21, 2002·Lancet·Chloe L ThioUNKNOWN Multicenter AIDS Cohort Study
Jan 14, 2003·Annual Review of Immunology·Daniel C DouekRichard A Koup
May 25, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ellen M TedaldiUNKNOWN HIV Outpatient Study (HOPS) Investigators
Sep 6, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Edgar Turner OvertonJudith A Aberg
Apr 8, 2006·AIDS Research and Therapy·Patricia Cornejo-JuárezLuis Enrique Soto-Ramírez
Sep 14, 2007·Scandinavian Journal of Infectious Diseases·Leilani Paitoonpong, Chusana Suankratay
Jan 8, 2008·The Journal of Infectious Diseases·Theodora E M S de Vries-SluijsMarchina E van der Ende
Aug 30, 2008·International Journal of STD & AIDS·H Nina KimMari M Kitahata
May 14, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Georgios K NikolopoulosAngelos Hatzakis
Feb 26, 2011·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Patricia M FlynnUNKNOWN Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN)
Jan 1, 2013·Vaccine·Vania Baptista LopesMarchina E van der Ende
Jan 15, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Solen KernéisPierre-Yves Boëlle
Oct 31, 2014·World Journal of Gastroenterology : WJG·Hsin-Yun SunChien-Ching Hung
Aug 5, 2017·Best Practice & Research. Clinical Gastroenterology·Kali Zhou, Norah Terrault
Jun 26, 2018·MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports·Sarah SchillieNoele P Nelson
Apr 3, 2019·Tropical Medicine and Infectious Disease·Darcy Wooten, Maile Y Karris

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.